Table 1.
Main characteristics of studies included in the meta-analysis.
| References | Cancer type | Sample size evaluable for TMB | Area | TMB sequencing method | Outcomes |
|---|---|---|---|---|---|
| Wang et al. (38) | NSCLC | 50 | Asian | Targeted NGS | ORR, PFS |
| Van Allen et al. (39) | Melanoma | 110 | Western | WES | ORRa, PFSa, OSa |
| Teo et al. (14) | Urothelial carcinoma | 60 | Western | Targeted NGS | ORR, PFS, OS |
| Tang et al. (26) | Melanoma or urologic cancers | 23 | Asian | Targeted NGS | ORR, PFSb, OSb |
| Snyder et al. (11) | Melanoma | Discovery: 25; validation: 39 | Multiple areas | WES | OS (discovery and validation cohorts) |
| Roszik et al. (40) | Melanoma | 76 | Western | Targeted NGS | OS |
| Roh et al. (41) | Melanoma | 21 | Western | WES | ORRa |
| Rizvi et al. (13) | NSCLC | 34 | Western | WES | ORR |
| Rizvi et al. (19) | NSCLC | 240 | Western | Targeted NGS | PFS |
| Ricciuti et al. (42) | SCLC | 52 | Western | Targeted NGS | ORR, PFS, OS |
| Riaz et al. (43) | NSCLC | 68 | Western | WES | ORRa, OSa |
| Ready et al. (44) | NSCLC | 98 | Western | Targeted NGS | ORR, PFSb |
| Morrison et al. (27) | Melanoma | 160 | Western | Targeted NGS | ORRa, OSb |
| Mishima et al. (28) | Gastric cancer | 80 | Asian | Targeted NGS | ORR, PFS |
| Huang et al. (29) | Esophageal carcinoma | 23 | Asian | WES | PFS |
| Huang et al. (46) | Gastric/ gastroesophageal junction cancer | 20 | Asian | WES | ORR |
| Hellmann et al. (20) | NSCLC | 75 | Western | WES | ORR, PFS |
| Hellmann et al. (47) | SCLC | Anti-PD-1: 133; anti-PD-1 plus anti-CTLA-4: 78 | Western | WES | ORR, PFSb |
| Goodman et al. (48) | Diverse cancers | 102 | Western | Targeted NGS | ORR, PFS, OS |
| Cristescu et al. (50) | Pan-tumor, HNSCC, melanoma | Pan-tumor: 119; HNSCC: 107; melanoma: 89 | Western | WES | ORR, PFS |
| Chae et al. (51) | NSCLC | 82 | Western | Targeted NGS | PFS, OS |
| Carbone et al. (52) | NSCLC | 158 | Multiple areas | WES | ORR, PFSb |
| Johnson et al. (12) | Melanoma | 65 | Western | Targeted NGS | ORR, PFS, OS |
| Hugo et al. (45) | Melanoma | 38 | Western | WES | ORRa, OSa |
| Samstein et al. (17) | Diverse cancers | 1662 | Western | Targeted NGS | OSa |
| Gandara et al. (49) | NSCLC | POPLAR: 105a; OAK: 324a | Multiple areas | Targeted NGS | ORRa, PFSa, OSa |
| Fang et al. (53) | NSCLC | 73 | Asian | WES | ORR, PFS |
| Schrock et al. (54) | Colorectal cancer | 22 | Western | Targeted NGS | ORR, PFS |
| Chae et al. (55) | NSCLC | 20 | Western | Targeted NGS | PFS, OS |
a
The value was calculated from original data of the study.
b
The value was calculated from Kaplan–Meier curves in the article.
NSCLC, non-small-cell lung cancer; SCLC, small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; PD-1, programmed cell death 1; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; TMB, tumor mutation burden; NGS, next generation sequencing; WES, whole exome sequencing; ORR, objective response rate/overall response rate; PFS, progression-free survival; OS, overall survival.